<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04408937</url>
  </required_header>
  <id_info>
    <org_study_id>CLJN452A2113</org_study_id>
    <nct_id>NCT04408937</nct_id>
  </id_info>
  <brief_title>The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.</brief_title>
  <official_title>A Randomized, Investigator and Subject Blinded, Multicenter, Parallel-arm Study to Determine the Safety and Tolerability of Tropifexor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether dosing tropifexor is safe and tolerable.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, subject and investigator blinded, multicenter, parallel-arm study to&#xD;
      assess the safety and tolerability of tropifexor dosed in the evening as compared to dosing&#xD;
      in the morning in subjects with non-alcoholic steatohepatitis (NASH). Subjects whose&#xD;
      eligibility was confirmed were randomized with stratification by domicile status at Day 1 of&#xD;
      the treatment period into tropifexor (200 μg) AM dose group (hereafter referred to as AM dose&#xD;
      group) or tropifexor (200 μg) PM dose group (hereafter referred to as PM dose group) in a 1:1&#xD;
      ratio. Subjects in the AM dose group took tropifexor in the morning and placebo in the&#xD;
      evening while subjects in the PM dose group took placebo in the morning and tropifexor in the&#xD;
      evening for 4 weeks in a blinded manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2020</start_date>
  <completion_date type="Actual">November 4, 2020</completion_date>
  <primary_completion_date type="Actual">November 4, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in fasting circulating LDL-C levels after 2 weeks of tropifexor treatment</measure>
    <time_frame>week 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting circulating High density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) levels over 4 weeks of treatment</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ALT, AST and GGT over 4 weeks of treatment</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters include but not limited to Cmax (ng/ml) will be assessed in the domiciled patients</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters include but not limited to area under the curve (AUC) will be assessed in the domiciled patients</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>tropifexor AM 200 micrograms and Placebo (PM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor 200 μg (AM) and Placebo (PM) once daily each</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tropifexor PM 200 micrograms and Placebo (AM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor 200 μg (PM) and Placebo (AM) once daily each</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triopifexor</intervention_name>
    <description>Tropifexor as a dry blend in hard gelatin capsules for oral administration</description>
    <arm_group_label>tropifexor AM 200 micrograms and Placebo (PM)</arm_group_label>
    <arm_group_label>tropifexor PM 200 micrograms and Placebo (AM)</arm_group_label>
    <other_name>LJN452</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules for oral administration</description>
    <arm_group_label>tropifexor AM 200 micrograms and Placebo (PM)</arm_group_label>
    <arm_group_label>tropifexor PM 200 micrograms and Placebo (AM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Presence of Liver Disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of other investigational drugs at the time of enrollment, or within 5 half-lives&#xD;
             of enrollment, or within 30 days, whichever is longer; or longer if required by local&#xD;
             regulations.&#xD;
&#xD;
          -  Subjects taking the following medicines UNLESS on a stable dose (within 25% of&#xD;
             baseline dose) for at least 3 months before randomization:&#xD;
&#xD;
        Type 1 diabetes and Uncontrolled Type 2 diabetes defined as Glycated hemoglobin (HbAlc) ≥&#xD;
        9.5% at screening&#xD;
&#xD;
        -Calculated estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1.73m2 (using the&#xD;
        Modification of diet in renal disease (MDRD) formula) Subjects with contraindications to&#xD;
        Magnetic resonance imaging (MRI) imaging.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madison</city>
        <state>Alabama</state>
        <zip>35758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014-3616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208-2312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tropifexor</keyword>
  <keyword>FXR agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

